Americans Will Foot the Bill for Germany's New Drug Price Controls
Germany's new drug price controls are expected to shift the financial burden of pharmaceutical innovation onto American patients. As Germany imposes spending caps and demands discounts from drugmakers, the U.S. continues to bear a disproportionate share of global drug development costs. Experts argue that without pushback, other countries may follow Germany’s example, further entrenching this imbalance.
- ▪Germany has introduced policies to cap healthcare spending and force drugmakers to offer steep discounts on medicines.
- ▪Drugmakers recoup research and development costs primarily from the U.S. market, where patients pay significantly more for the same drugs.
- ▪The United States generates about 75% of global pharmaceutical profits despite representing only 25% of global GDP.
- ▪President Trump has pressured allies like the UK to increase spending on medicines and may use Section 301 investigations to challenge unfair pricing practices.
- ▪If unchecked, Germany's approach could encourage other nations to maintain low drug prices at the expense of U.S. consumers.
Opening excerpt (first ~120 words) tap to expand
Americans Will Foot the Bill for Germany's New Drug Price Controls Drew Johnson | 6:52 PM on May 04, 2026 Photo by Christina Victoria Craft on Unsplash Germany just found a new way to lower its own healthcare costs: make Americans pay more.In late April, German policymakers proposed changes that cap spending growth, restrict care, and force drugmakers to provide steep discounts. Advertisement googletag.cmd.push(function () { googletag.display("div-gpt-300x250_3"); //googletag.pubads().refresh([gptAdSlot["div-gpt-300x250_3"]]) }); These changes are supposed to save Germany money. But drugmakers still need to recoup the high costs of research and development.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at PJ Media.
Discussion
0 commentsMore from PJ Media
